Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Assessment of Anorectal Function in Patients With Inflammatory Bowel Disease

A legfontosabb adatok

Ki végzi
Region Örebro County
Hol
Svédország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
70 fő, tervezett
Kezdés
2021. szept. 1.
Várható befejezés
2027. dec. 30.
A vizsgálat típusa
Megfigyeléses, 4 csoport
A vizsgált kezelések
  • Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS
  • Exposure 2: Changes in anorectal motor function or compliance.
A regiszteradat frissítve
2022. február 3.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for healthy volunteers and for people with moderate to severe inflammatory bowel disease (IBD) that is in remission. Patients may have ongoing bowel symptoms or no symptoms.

Életkor
18 Years to 65 Years
Nem
All
A betegség stádiuma
Patients: moderate to severe IBD in remission (not active). Groups include ulcerative colitis (UC), and Crohn's disease (CD) affecting the lower colon or the area around the anus.
Korábbi kezelés
No current or recent drugs that affect the bowel or mood, such as antidepressants. No probiotics or herbal products that affect the bowel. No systemic steroids in the last 2 weeks. People taking antidiarrhoeal drugs or laxatives can join after a 48 h break.

A részvétel fő kizáró okai

  • Active IBD
  • Past anal or pelvic surgery, including procedures during childbirth
  • Diabetes, heart, kidney or liver disease
  • Alcohol or drug abuse
  • Healthy volunteers: any bowel disease, bowel symptoms or psychiatric disease

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Healthy volunteers
  • Symptomatic IBD patients: Moderate to severe IBD in remission with persistent symptoms as reported by symptom index and short health scale
  • Asymptomatic IBD patients: moderate to severe IBD in remission without symptoms

Ki nem vehet részt

  • anal or pelvic surgery, inclusive interventions during delivery
  • concurrent or recent treatment with drugs affecting intestinal function or mood (antidepressants), nutritional supplements or herb products affecting intestinal function (probiotics), abuse of alcohol or drugs, and a recent (< 2 weeks) history of systemic steroid therapy; IBD patients
  • anal or pelvic surgery, inclusive interventions during delivery
  • concurrent or recent treatment with drugs affecting intestinal function or mood (antidepressants), nutritional supplements or herb products affecting intestinal function (probiotics), abuse of alcohol or drugs, and a recent (< 2 weeks) history of systemic steroid therapy. Patients taking antidiarrhoeal or laxatives can be included after a 48 h washout period
  • gastrointestinal disease, functional gastrointestinal symptoms,
  • psychiatric disease
  • diabetes, cardiovascular, renal, or hepatic disease,
  • active disease
  • diabetes, cardiovascular, renal, or hepatic disease,
  • Healthy volunteers:

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Active inflammatory bowel disease (IBD) causes disabling symptoms such as diarrhea, involuntary loss of bowel control, abdominal pain and urges to pass stool. However, even patients with inactive IBD frequently experience such symptoms. The cause is not well understood and the functionality of the bowel in IBD patients is underexplored.

A teljes eredeti leírásKevesebb

Earlier studies show a wide range of results, but most find that patients with IBD in remission are up to four times as likely to report gastrointestinal symptoms when compared to healthy controls.

Chronic inflammation may cause changes of the bowel wall, like increased collagen deposits (fibrosis) and thus cause symptoms, but the absence of active inflammation in combination with presence of symptoms may also be regarded as resembling the clinical condition of irritable bowel syndrome (IBS).

IBS is characterized by abdominal pain and changes in stool frequency and consistence and is often associated with disorders like depression and anxiety. Up to a third of IBD patients without signs of disease activity meet the criteria for IBS (irritable bowel syndrome. It can be speculated that an IBD diagnosis is a distressing event that can induce mood disorders, and an IBS-like condition.

Characterization of IBS patients relies on the Rome IV symptom criteria, symptom severity scales and measurements of rectal sensibility and rectal compliance using a barostat procedure.

Motor function assessment relies on anorectal manometry which detects abnormalities of muscle function and coordination. Recently, a standardized high-resolution anorectal manometry protocol (HRAM) was published which also evaluates sensitivity and compliance. The level of agreement between the barostat method and the HRAM testing procedure regarding sensibility and rectal compliance is largely unknown.

Recent studies have associated gut microorganisms, genetic factors, and proteins with various aspects of IBD. There is evidence that these potential markers may reflect non-inflammatory processes such as fibrosis.

The aim of this study is to explore the anorectal function in symptomatic patients with inactive IBD compared to healthy volunteers and asymptomatic patients, evaluate symptom severity and psychological parameters and perform molecular characterization.

The level of agreement of rectal sensitivity and compliance measurements with the barostat method and HRAM protocol will also be evaluated.

A vizsgálat 4 csoportja

  • Healthy volunteers

    Healthy volunteers aged 18-to 65

    Kezelés: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS és Exposure 2: Changes in anorectal motor function or compliance.

  • Asymptomatic patients with quiescent IBD

    Asymptomatic patients with IBD in remission.

    Kezelés: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS és Exposure 2: Changes in anorectal motor function or compliance.

  • Symptomatic patients with quiescent UC

    Symptomatic patients with UC in remission

    Kezelés: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS és Exposure 2: Changes in anorectal motor function or compliance.

  • Symptomatic patients with quiescent CD with anorectal involvement

    Symptomatic patients with CD with distal involvement of the colon or perianal disease

    Kezelés: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS és Exposure 2: Changes in anorectal motor function or compliance.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Assessment of Anorectal Function in Healthy Volunteers and Patients With Inflammatory Bowel Disease
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT05185609: ki vehet részt
A regiszteradat frissítve
2022. február 3.